{"schema_version":"secwatch.filing_event.v1","accession":"0001651308-26-000008","form_type":"8-K","ticker":"ONC","cik":"0001651308","company_name":"BeOne Medicines Ltd.","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.665862+00:00","generated_at":"2026-05-15T06:23:42.054919+00:00","sec_items":["2.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BeOne Medicines reports FY2025 revenue $5.34B, R&D spend $2.15B","bullets":["Revenue $5.34B, up 40% YoY; gross margin 87.5% (China 66.6%, ex-China 97.0%)","R&D total $2.15B, up 10% YoY; largest pipeline: sonrotoclax $176.7M, BRUKINSA $97.6M","Key product production 6.27M vials, sales 5.99M vials; inventory 2.91M vials at Dec 31, 2025","U.S. GAAP vs PRC GAAP differences: stock compensation and lease accounting treatments vary"],"urls":{"canonical":"https://secwatch.observer/filing/0001651308-26-000008","json":"https://secwatch.observer/filing/0001651308-26-000008.json","markdown":"https://secwatch.observer/filing/0001651308-26-000008.md","text":"https://secwatch.observer/filing/0001651308-26-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000008/0001651308-26-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651308/000165130826000008/bgne-20260414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:23:42.054919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}